<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18367">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01967810</url>
  </required_header>
  <id_info>
    <org_study_id>ANG1005-CLN-03</org_study_id>
    <nct_id>NCT01967810</nct_id>
  </id_info>
  <brief_title>ANG1005 in Patients With Recurrent High-Grade Glioma</brief_title>
  <official_title>A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiochem Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angiochem Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells
      in patients with high-grade glioma. Another purpose of this study is to assess the efficacy,
      safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) (Arms 1 and 3)</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the radiologic ORR in bevacizumab-naïve recurrent Glioblastoma multiforme (GBM) patients (Arm 1)and in recurrent anaplastic glioma WHO Grade III patients (Arm 3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS3 (Arm 2)</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the progression-free survival at 3 months (PFS3) in bevacizumab-refractory recurrent GBM patients (Arm 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR in Arm 2</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the ORR in Arm 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS at 3, 6 and 12 months</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the number of patients without progression at 3, 6 and 12 months in Arms 1 and 3
To determine the number of patients without progression at 6 and 12 months in Arm 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median PFS</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the median progression-free survival in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the median duration of response in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the median overall survival in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>At 0 h (pre-dose), at the end of infusion, at 2 and 4 hours post-dose on Day 1 of treatment cycles 1 and 3 (Week 1 and Week 9)</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the drug concentration and distribution in the blood (plasma)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Glioma</condition>
  <condition>Glioblastoma</condition>
  <condition>Brain Tumor, Recurrent</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANG1005 administered to bevacizumab-naive recurrent GBM patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANG1005 and possibly bevacizumab administered to bevacizumab-refractory recurrent GBM patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANG1005 administered to recurrent WHO Grade III anaplastic glioma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANG1005</intervention_name>
    <description>ANG1005 at a starting dose of 650 mg/m2 by intravenous  infusion once every 3 weeks</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>GRN1005</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>For patients enrolled in the bevacizumab-refractory in recurrent GBM (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years old

          2. GBM and GBM variants, WHO Grade III anaplastic glioma diagnosis confirmed

          3. Radiologically confirmed recurrent and bi-dimensionally measurable disease per
             Response Assessment in Neuro-Oncology (RANO) criteria

          4. Neurologically stable

          5. For bevacizumab-refractory patients, radiologic demonstration of tumor progression
             during bevacizumab therapy

          6. Karnofsky performance status (KPS) ≥ 70

        Exclusion Criteria:

          1. More than three relapses

          2. Previous ANG1005/GRN1005 treatment

          3. Radiotherapy within 3 months.

          4. Therapy with bevacizumab within 4 weeks prior to screening for recurrent WHO grade
             III anaplastic glioma patients (Arm 3)

          5. Evidence of significant intracranial hemorrhage

          6. Previous taxane treatment

          7. Prior therapy with bevacizumab for bevacizumab-naïve patients (Arm 1)

          8. NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 Grade ≥ 2 neuropathy

          9. Inadequate bone marrow reserve
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul Castaigne, MD</last_name>
    <role>Study Director</role>
    <affiliation>Angiochem Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronica Burdusel, M.Sc.</last_name>
    <phone>514-788-7800</phone>
    <phone_ext>206</phone_ext>
    <email>vburdusel@angiochem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Betty Lawrence</last_name>
    <phone>514-788-7800</phone>
    <phone_ext>205</phone_ext>
    <email>blawrence@angiochem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moores UC San Diego Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Brechlin, MBA, MPH</last_name>
      <phone>858-822-5352</phone>
      <email>jbrechlin@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bradley Brown</last_name>
      <phone>858-822-5377</phone>
      <email>bdbrown@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Santosh Kesari, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leanne Fountas</last_name>
      <phone>312-695-1342</phone>
      <email>leanne.fountas@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Priya Kumthekar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karly Griffin</last_name>
      <phone>617-632-6749</phone>
      <email>karly_griffin@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Wen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janlyn Murphy</last_name>
      <phone>617-667-1832</phone>
      <email>jmurphy7@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Wen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Wong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edwin Nunez, CCRP</last_name>
      <phone>617-643-4395</phone>
      <email>enunez2@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Wen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tracy T Batchelor, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15323</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Grzejka, BSN, RN</last_name>
      <phone>412-623-4891</phone>
      <email>grzejkac@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melinda Vargas-Jaffe, BSN, RN</last_name>
      <phone>412-235-1320</phone>
      <email>vargasjaffema@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jan Drappatz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy of Texas Health Science Center in San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherie Noles</last_name>
      <phone>210-450-5964</phone>
      <email>nolesc@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Brenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emily Couric Clinical Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Loomba, BS, CCRC</last_name>
      <phone>434-924-5859</phone>
      <email>jjl4d@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Monika Thielen</last_name>
      <phone>434-243-9900</phone>
      <email>Mjt3c@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Schiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23349317</url>
    <description>A Phase I sudy of ANG1005 (GRN1005) in recurrent malignant glioma</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>brain cancer</keyword>
  <keyword>brain tumor</keyword>
  <keyword>recurrent</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
